<DOC>
	<DOCNO>NCT01976936</DOCNO>
	<brief_summary>This trial phase 2 randomize safety study ischemic stroke patient randomly assign within 24 hour symptom onset placebo standard dose lovastatin versus short-term high-dose lovastatin 640 mg per day 3 day . The primary outcome Phase 2 study musculoskeletal hepatic toxicity , define clinical laboratory criterion , 3-month follow-up period ( Â± 1 week ) . Secondary outcome include neurological outcome ( National Institute Health ( NIH ) Stroke Scale ) , functional outcome ( Barthel Index ) , handicap ( modified Rankin score ) . Effects inflammatory marker lipid level also assess .</brief_summary>
	<brief_title>Neuroprotection With Statin Therapy Acute Recovery Trial Phase 2</brief_title>
	<detailed_description>This phase 2 randomize , blind control safety study patient ischemic stroke . The time window enrollment within 0-24 hour symptom onset . For patient find stroke awaken , assume stroke occur last time patient know normal . All patient identify stroke acute care team emergency room participate center , case , floor service hospital ( i.e. , patient stroke occur hospital ) . If preliminary data indicate patient meet eligibility criterion patient ( legally authorize representative ) approach participation study , consent obtain . Surrogate consent allow center permit accord regulation . Patients consented surrogate subsequently regain capacity , approach reconsented continue study . The intervention choose trial either ( 1 ) placebo patient take statin time admission OR lovastatin 80 mg place regular statin patient take statin ( atorvastatin , simvastatin , rosuvastatin , pravastatin , fluvastatin , lovastatin ) time enrolment VERSUS ( 2 ) oral lovastatin dosage 640 mg daily 3 day . The time first dose consider time 0 . Patients administer total daily dose four daily divide dos ( i.e. , QID schedule ) . After initial 3 day acute dosage , patient receive statin therapy discretion treat physician .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Jaundice</mesh_term>
	<mesh_term>Rhabdomyolysis</mesh_term>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<criteria>1 . Age &gt; 18 2 . Satisfies criteria ischemic stroke : acute focal neurological deficit likely ischemic vascular origin . 3 . Patient legally authorize representative provide write informed consent prior study entry . Patient regain capacity provide his/her write consent remain study . 4 . Patient receive first treatment dose within 024 hour stroke onset . For patient find stroke awaken , assume stroke occur last time patient know normal . 5 . Patient pretreatment brain CT scan compatible ischemic stroke exclude hemorrhagic nonvascular etiology symptom . 6 . Patients take statins time stroke may include . 7 . Patients receive standard dose intravenous tPA mechanical interventional procedure may enrol . 1 . Brain imaging study show lesion ischemic stroke could explain patient 's symptom ( intracranial subarachnoid hemorrhage , arteriovenous malformation , aneurysm , multiple sclerosis , tumor , abscess ) . Asymptomatic meningioma allow . 2 . Mild stroke , define NIH Stroke Scale &lt; 2 . 3 . Weight &lt; 50 kg . 4 . Patient comatose , regardless etiology ( &gt; 4 point first three item NIHSS ) . 5 . History intolerance allergic reaction statin ( myotoxicity , hepatic dysfunction , rash , etc . ) 6 . Use drug within past 30 day utilize cytochrome CYP3A pathway ( cyclosporine , itraconazole , ketoconazole , erythromycin , clarithromycin , nefazodone , posaconazole , voriconazole , dronedarone , diltiazem , colchicine ranolazine ) . 7 . Use drug within past 30 day increase risk myotoxicity statin ( gemfibrozil , fibrates , niacin , amiodarone , verapamil ) . 8 . Baseline major electrolyte disturbance ( sodium &lt; 125 &gt; 150 , potassium &lt; 3.0 &gt; 5.5 ) . 9 . Recent major trauma ( &lt; 3 month ) . 10 . Hypothermia ( body temperature &lt; 96F ) . 11 . Baseline hypoxia ( define oxygen saturation &lt; 92 % room air ) . 12 . History likely proven systemic viral infection within 30 day . 13 . Known HIV infection use protease inhibitor . 14 . Endocarditis likely cause stroke . 15 . Mitochondrial disorder likely cause stroke . 16 . Pregnancy lactation . 17 . History rhabdomyolysis , myopathy , severe muscle disease . 18 . History hepatitis , decompensated liver disease ( ascites , bleed varix encephalopathy ) , liver failure . 19 . Liver function test ( ALT , AST ) &gt; 2 X upper limit normal . 20 . Unstable cardiovascular ( include uncontrolled hypertension ) , pulmonary , gastrointestinal , hepatic musculoskeletal disease . 21 . Patient evidence severe congestive heart failure history endstage cardiovascular disease ( e.g . CHF NYHA Class III IV unstable angina ) . 22 . Abnormal ECG showing : Hemodynamically significant arrhythmia frequent PVCs ( &gt; 5/minute ) ( control atrial arrhythmia exclusion ) ; evidence acute myocardial infarction ; Mobitz Type II 2nd degree AV block 3rd degree AV block ; ventricular tachycardia ventricular fibrillation . 23 . Significant renal insufficiency , indicate serum creatinine &gt; 2.0 mg/dl . 24 . Hypoglycemia ( glucose &lt; 60 mg/dl ) diabetic ketoacidosis unresponsive therapy . 25 . Any hematologic abnormality : WBC &lt; 3.0 x 103/mm3 ; Platelet count &lt; 50,000/mm3 26 . Received investigational drug within 30 day . 27 . Severe behavioral social problem may interfere conduct clinical study procedure . 28 . Patient unlikely , investigator 's opinion , complete study return followup visit reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Rhabdomyolysis</keyword>
	<keyword>Jaundice</keyword>
</DOC>